Measuring Levels of Osteopontin as a potential biomarker for Hepatocellular Carcinoma in Syrian patients
Gastroenterology and Hepatology from Bed to Bench,
3 April 2017
Aim: This study aims to evaluate plasma osteopontin (OPN) levels as a potential biomarker for hepatocellular carcinoma (HCC).
Background: Osteopontin (OPN) is a secreted glycoprotein that is associated with tumorigenesis and metastasis.
Methods: We measured plasma levels of OPN in 26 HCC patients, 27 patients with chronic liver diseases (CLD), and 15 healthy control individuals using a standardized ELISA kit.
Results: The mean plasma OPN level was significantly higher in the HCC group than the CLD group or the normal control group (p-value =0.001/<0.0001). Plasma OPN levels were significantly higher in patients with a tumor size >5 cm in diameter than those with tumors ?5 cm (p=0.02). OPN levels in the HCC group were not significantly affected by advancing degree of Child-Pugh class. Diagnostic sensitivity and specificity of OPN for HCC were 61% and 82%, respectively (cut-off value: 118.69ng/mL). The area under the ROC curve (AUC) value for OPN was 0.784. However, the AUC value was 0.844 for AFP.
Conclusion: The plasma levels of OPN show low diagnostic accuracy for HCC compared to AFP. However, OPN may have a complementary role in diagnosing HCC in patients with non-diagnostic levels of AFP.
- Osteopontin. Hepatocellular carcinoma. Chronic liver diseases. Diagnosis. Biomarker.
- Abstract Viewed: 593 times
- PDF Downloaded: 101 times